Institution Directory

Clinical trials at NYU Langone Health

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1137

Shown on this page

Current sort

Live official records

Conditions: Radiation-Induced Xerostomia and Hyposalivation
Interventions: RXRG001, Placebo; Biological
Lead sponsor: RiboX Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Palo Alto, California • Iowa City, Iowa • Baltimore, Maryland + 2 more

Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Elironrasib, Daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Duarte, California • Orange, California • Sacramento, California + 17 more

Conditions: BRAF V600E Mutation
Interventions: Plixorafenib, Retifanlimab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma
Interventions: LY4337713; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 20
States / cities: Newport Beach, California • Stanford, California • Miami, Florida + 14 more

Conditions: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
Interventions: Debio 0123, Temozolomide, Radiotherapy; Drug · Radiation
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 8
States / cities: Chicago, Illinois • New York, New York • Dallas, Texas + 4 more

Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Interventions: Aficamten, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 60
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 46 more

Conditions: Overweight, Obesity
Interventions: Eloralintide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 59
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 52 more

Conditions: Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
Interventions: Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride, Temozolomide; Other · Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 19 more

Conditions: Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions: Setidegrasib, Oxaliplatin, Leucovorin, Irinotecan, fluorouracil, liposomal irinotecan, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 49
States / cities: Tucson, Arizona • Fort Smith, Arkansas • Fullerton, California + 43 more

Conditions: Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor
Interventions: Pharmacokinetic Study, Ulixertinib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 105
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 82 more

Conditions: Atopic Keratoconjunctivitis
Interventions: DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution; Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 10 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Jacksonville, Florida • Miami, Florida • Morrow, Georgia + 5 more

Conditions: Long QT Syndrome (LQTS) 2
Interventions: baseline lead-in, THRV-1268; Other · Drug
Lead sponsor: Thryv Therapeutics, Inc.; Industry
Eligibility: 15 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 6 more

About this NYU Langone Health institution page

What this page lists: ClinicalTrials.gov records that list NYU Langone Health in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at NYU Langone Health

Filter and sort this campus

Live official records

Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)

About this NYU Langone Health institution page